ABSTRACT Introduction Differentiated thyroid carcinomas (DTCs) are treated with (near-)
total thyroidectomy and radioiodine therapy. Recently, the use of highly sensitive …

Background Obesity is a risk factor for several cancers, including differentiated thyroid
cancer (DTC). Moreover, it has also been investigated as a potential risk factor for …

Risk assessment is the cornerstone of contemporary management of thyroid cancer.
Following thyroid surgery, an initial risk assessment of recurrence and disease-specific …

Background: The prevalence and clinical significance of de novo detection of anti-
thyroglobulin antibodies (TgAbs) during the follow-up of patients with differentiated thyroid …

Prognosis in Differentiated Thyroid Cancer (DTC) patients is excellent, but a significant
degree of overtreatment still exists because of the inability to accurately identify small patient …

Context Differentiated thyroid cancer (DTC) has an excellent prognosis, but up to 20% of
patients with DTC have disease events after initial treatment, indistinctly defined as …

Purpose To develop a nomogram for predicting biochemical incomplete response (BIR) in
the dynamic risk stratification (DRS) of papillary thyroid carcinoma (PTC) patients without …

Basal thyroglobulin (b-Tg) measured with second-generation assay or stimulated Tg (s-Tg)
can be used to define the response to therapy of differentiated thyroid carcinoma. However …

Anti-thyroglobulin antibodies are commonly identified in patients with differentiated follicular
cell-derived thyroid cancer. When present, they interfere with the measurement of …

In patients with differentiated thyroid cancer, stimulated thyroglobulin (sTg) levels after
thyroid hormone withdrawal (THW) at remnant ablation (RA) and at 6 to 12 months are …